Piperacillin + tazobactam

Generic Medicine Info
Hypersensitivity to piperacillin, tazobactam, or any other penicillin-antibacterial agent. History of acute severe allergic reaction to any other β-lactam active substances (e.g. cephalosporin, monobactam or carbapenem).
Special Precautions
Patient w/ cystic fibrosis, history of seizure disorder. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients w/ low K reserves. Monitor creatinine, BUN, CBC w/ differential, prothrombin time, partial thromboplastin time, LFTs, urinalysis, signs of bleeding, signs of anaphylaxis during 1st dose.
Adverse Reactions
GI effects (e.g. diarrhoea, nausea, constipation), rash (maculopapular, bullous, urticarial, eczemoid), pruritus, fever, headache, insomnia; adverse reactions at inj site (phlebitis, pain, inflammation, thrombophlebitis, oedema). Decreases in Hb and haematocrit, thrombocytopenia, increases in platelet count, transient eosinophilia, leucopenia, neutropenia; positive Coombs' test results, prolonged prothrombin time and partial thromboplastin time. Increases in serum concentrations of creatinine and BUN, changes in serum electrolytes, transient increases in AST, ALT, alkaline phosphatase and bilirubin.
Potentially Fatal: Serious, anaphylactic reactions, antibiotic-induced pseudomembranous colitis, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Drug Interactions
Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.
CIMS Class
ATC Classification
J01CA12 - piperacillin ; Belongs to the class of penicillins with extended spectrum. Used in the systemic treatment of infections.
J01CG02 - tazobactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on piperacillin + tazobactam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in